ADIL · Adial Pharmaceuticals, Inc. · Financials
$4.86
-0.35 (-6.72%)
At close · Sep 18
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“the Company has concluded that there is substantial doubt about its ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$13.13M
Shares
2.63M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Net Income
-$7.98M
+39.6%
FY2025
Diluted EPS
-$11.93
+82.5%
FY2025
Operating Cash Flow
-$6.49M
+6.2%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| $2.01M | $2.62M | $3.23M | $1.27M | $1.95M | $8.4M | $5.85M | $3.97M | $368.46K | $182.11K | |
| $9.48M | $5.18M | $5.06M | $5.62M | $8.91M | $9.34M | $5.07M | $4.28M | $6.62M | $813.18K | |
| $565 | $565 | $565 | $564 | $564 | $565 | $564 | $565 | $563 | $565 | |
| $57.68M | $7.8M | $8.28M | $6.89M | $10.86M | $19.29M | $10.93M | $8.24M | $6.99M | $995.29K | |
| — | — | — | — | $550K | — | — | — | — | — | |
| -$57.68M | -$7.8M | -$8.28M | -$6.89M | -$10.86M | -$19.29M | -$10.93M | -$8.24M | -$6.99M | -$995.29K | |
| $195.28K | $149.57K | $178.66K | $69.78K | $63.34K | $6539 | $32.5K | $95.23K | $7392 | $367 | |
| -$125.11K | -$177.71K | -$4.91M | -$113.94K | $63.34K | -$228.68K | $35K | -$346.53K | -$4.64M | -$144.17K | |
| $81.09K | $67.97K | -$552.18K | -$193.88K | — | — | — | — | — | — | |
| — | -$7.98M | -$13.2M | -$7M | -$10.8M | -$19.52M | -$10.89M | -$8.59M | -$11.63M | -$1.14M | |
| — | — | — | — | -$502 | -$94.08K | — | — | — | — | |
| -$57.8M | -$7.98M | -$13.2M | -$5.12M | -$12.73M | -$19.42M | -$10.89M | -$8.59M | -$11.63M | -$1.14M | |
| USD/shares | -$11.53 | -$11.93 | -$68.01 | -$90.00 | -$317.75 | -$650.00 | — | — | — | — |
| USD/shares | -$11.53 | -$11.93 | -$68.01 | -$90.00 | -$317.75 | -$650.00 | — | — | — | — |
| shares | — | 668.63K | 194.06K | — | 40.06K | 29.74K | 19.94K | 15.76K | 7614.9808 | 5223.016 |
| shares | — | 668.63K | 194.06K | 56.99K | 40.06K | 29.74K | 19.94K | 15.76K | 389.0912 | 278.8512 |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 1.84×
EV/EBIT
—
P/E (TTM)
—
Peer median 2.85×
Peer medians compare against the 228 similar-size Biotechnology companies (of 533 listed).